File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemoprevention of gastric cancer

TitleChemoprevention of gastric cancer
Authors
Issue Date2006
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.eurojgh.com
Citation
European Journal Of Gastroenterology And Hepatology, 2006, v. 18 n. 8, p. 867-871 How to Cite?
AbstractGastric cancer is the second commonest cause of cancer-associated death in the world. The high mortality is largely attributed to the huge number of at-risk individuals as well as the delay in presentation. Hence, chemoprevention of gastric cancer appears to be the most promising approach in reducing the incidence and mortality related to this cancer. Among various chemoprevention strategies, Helicobacter pylori eradication is the one being most extensively examined. Results from several large-scale prospective randomized studies, however, showed marginal benefits of H. pylori eradication on regression of premalignant gastric lesions. Moreover, there is no significant reduction in gastric cancer incidence. Similarly, ascorbic acid and/or beta-carotene supplementation have borderline effects on premalignant gastric lesions. Based on epidemiological data, the use of non-steroidal anti-inflammatory drugs is associated with a reduced risk of stomach cancer. Future studies should evaluate the role of other chemopreventive agents, particularly specific cyclooxygenase-2 inhibitors, in reducing the risk of gastric cancer. © 2006 Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/162994
ISSN
2015 Impact Factor: 2.093
2015 SCImago Journal Rankings: 0.867
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLeung, WKen_US
dc.contributor.authorSung, JJYen_US
dc.date.accessioned2012-09-05T05:26:21Z-
dc.date.available2012-09-05T05:26:21Z-
dc.date.issued2006en_US
dc.identifier.citationEuropean Journal Of Gastroenterology And Hepatology, 2006, v. 18 n. 8, p. 867-871en_US
dc.identifier.issn0954-691Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/162994-
dc.description.abstractGastric cancer is the second commonest cause of cancer-associated death in the world. The high mortality is largely attributed to the huge number of at-risk individuals as well as the delay in presentation. Hence, chemoprevention of gastric cancer appears to be the most promising approach in reducing the incidence and mortality related to this cancer. Among various chemoprevention strategies, Helicobacter pylori eradication is the one being most extensively examined. Results from several large-scale prospective randomized studies, however, showed marginal benefits of H. pylori eradication on regression of premalignant gastric lesions. Moreover, there is no significant reduction in gastric cancer incidence. Similarly, ascorbic acid and/or beta-carotene supplementation have borderline effects on premalignant gastric lesions. Based on epidemiological data, the use of non-steroidal anti-inflammatory drugs is associated with a reduced risk of stomach cancer. Future studies should evaluate the role of other chemopreventive agents, particularly specific cyclooxygenase-2 inhibitors, in reducing the risk of gastric cancer. © 2006 Lippincott Williams & Wilkins.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.eurojgh.comen_US
dc.relation.ispartofEuropean Journal of Gastroenterology and Hepatologyen_US
dc.subject.meshAnti-Bacterial Agents - Therapeutic Useen_US
dc.subject.meshAnti-Inflammatory Agents, Non-Steroidal - Therapeutic Useen_US
dc.subject.meshChemoprevention - Methodsen_US
dc.subject.meshDieten_US
dc.subject.meshHelicobacter Infections - Drug Therapyen_US
dc.subject.meshHelicobacter Pylori - Pathogenicityen_US
dc.subject.meshHumansen_US
dc.subject.meshStomach Neoplasms - Etiology - Prevention & Controlen_US
dc.titleChemoprevention of gastric canceren_US
dc.typeArticleen_US
dc.identifier.emailLeung, WK:waikleung@hku.hken_US
dc.identifier.authorityLeung, WK=rp01479en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/00042737-200608000-00010en_US
dc.identifier.pmid16825903-
dc.identifier.scopuseid_2-s2.0-33745843454en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33745843454&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume18en_US
dc.identifier.issue8en_US
dc.identifier.spage867en_US
dc.identifier.epage871en_US
dc.identifier.isiWOS:000239532000008-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLeung, WK=7201504523en_US
dc.identifier.scopusauthoridSung, JJY=24473715000en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats